2478-48-0

Basic information

• Product Name: <3-(benzyloxy)-4-methyl-2-nitrobenzoyl>-L-threonyl-D-valyl-L-prolyl-sarcosyl-N-methyl-L-valine lactone
• Synonyms: <3-(benzyloxy)-4-methyl-2-nitrobenzoyl>-L-threonyl-D-valyl-L-prolyl-sarcosyl-N-methyl-L-valine lactone
• CAS NO: 2478-48-0
• Molecular Weight: 750.849
• Mol File: 2478-48-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: <3-(benzyloxy)-4-methyl-2-nitrobenzoyl>-L-threonyl-D-valyl-L-prolyl-sarcosyl-N-methyl-L-valine lactone(CAS DataBase Reference)
• NIST Chemistry Reference: <3-(benzyloxy)-4-methyl-2-nitrobenzoyl>-L-threonyl-D-valyl-L-prolyl-sarcosyl-N-methyl-L-valine lactone(2478-48-0)
• EPA Substance Registry System: <3-(benzyloxy)-4-methyl-2-nitrobenzoyl>-L-threonyl-D-valyl-L-prolyl-sarcosyl-N-methyl-L-valine lactone(2478-48-0)

Safety Data

• Hazardous Substances Data: 2478-48-0(Hazardous Substances Data)

Usage

Description

<3-(benzyloxy)-4-methyl-2-nitrobenzoyl>-L-threonyl-D-valyl-L-prolyl-sarcosyl-N-methyl-L-valine lactone is a complex synthetic peptide with a unique chemical structure that features a benzene ring with a benzyloxy group, a methyl group, and a nitro group, as well as a lactone ring. It also contains amino acid residues including L-threonine, D-valine, L-proline, and N-methyl-L-valine. <3-(benzyloxy)-4-methyl-2-nitrobenzoyl>-L-threonyl-D-valyl-L-prolyl-sarcosyl-N-methyl-L-valine lactone has potential biological activity and could be utilized in medicinal chemistry for the development of novel pharmaceutical compounds. Further research and experimentation are required to determine its precise properties and potential uses.

Uses

Used in Pharmaceutical Industry:
<3-(benzyloxy)-4-methyl-2-nitrobenzoyl>-L-threonyl-D-valyl-L-prolyl-sarcosyl-N-methyl-L-valine lactone is used as a potential building block for the development of novel pharmaceutical compounds due to its complex structure and the presence of various functional groups that may interact with biological targets.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, <3-(benzyloxy)-4-methyl-2-nitrobenzoyl>-L-threonyl-D-valyl-L-prolyl-sarcosyl-N-methyl-L-valine lactone is used as a subject of study for understanding its biological activity and potential interactions with biological systems, which could lead to the discovery of new therapeutic agents.
Used in Drug Design and Development:
<3-(benzyloxy)-4-methyl-2-nitrobenzoyl>-L-threonyl-D-valyl-L-prolyl-sarcosyl-N-methyl-L-valine lactone is used as a template in drug design and development, where its unique structure may be exploited to create new drugs with specific therapeutic properties.

Upstream product

• 7536-35-8 2-nitro-3-benzyloxy-4-methylbenzoyl chloride 
• 98688-14-3 N-<3-(benzyloxy)-4-methyl-2-nitrobenzoyl>-O-(tert-butoxycarbonyl-N-methyl-L-valyl)-L-threonyl-D-valyl-L-prolylsarcosine ter-butyl ester 
• 6041-34-5 <3-(benzyloxy)-4-methyl-2-nitrobenzoyl>-L-threonyl-D-valyl-L-prolyl-sarcosine tert-butyl ester 
• 2441-62-5 <3-(benzyloxy)-4-methyl-2-nitro-benzoyl>-L-threonine 
• 5616-84-2 N-(benzyloxycarbonyl)threonyl-D-valylprolylsarcosine tert-butyl ester 
• 27483-27-8 N-(benzyloxycarbonyl)-D-valylprolylsarcosine tert-butyl ester 
• 5616-83-1 H-D-Val-Pro-Sar-OBu^t 
• 5616-82-0 N-(benzyloxycarbonyl)prolylsarcosine tert-butyl ester 
• 63219-23-8 [Methyl-((S)-pyrrolidine-2-carbonyl)-amino]-acetic acid tert-butyl ester 
• 98757-23-4 (S)-2-(tert-Butoxycarbonyl-methyl-amino)-3-methyl-butyric acid (1R,2S)-2-(3-benzyloxy-4-methyl-2-nitro-benzoylamino)-2-{(R)-1-[(S)-2-(carboxymethyl-methyl-carbamoyl)-pyrrolidine-1-carbonyl]-2-methyl-propylcarbamoyl}-1-methyl-ethyl ester 
• 6623-31-0 2-nitro-3-benzyloxy-4-methylbenzoic acid N-hydroxysuccinimide ester 

Downstream Products

• 21148-64-1 (3-hydroxy-4-methyl-2-nitrobenzoyl)-L-threonyl-D-valyl-L-prolyl-sarcosyl-N-methyl-L-valine lactone 
• 50-76-0 actinomycin D 

Relevant articles and documents

Toward the design of an RNA:DNA hybrid binding agent

One characteristic function of the retroviruses, which is generally not found in normal eukaryotic cells, is production of a long RNA:DNA hybrid in the viral replication phase. If agents are designed which bind only to the RNA:DNA hybrid, but neither to DNA nor to RNA, such agents will be able to inhibit specifically the RNase H activity of retroviral reverse transcriptase, and therefore will suppress viral replication. Actinomycin D binds to double-stranded DNA, but not to RNA, because steric hindrance between the 2-amino group of the phenoxazinone ring and the 2'-hydroxyl group of RNA prevents intercalation of the antibiotic. However, if the C8-H in the phenoxazinone ring is replaced by an aromatic nitrogen N8, a strong hydrogen bond acceptor, this analog (N8-actinomycin D) might be able to bind intercalatively to an RNA:DNA hybrid by forming an additional hydrogen bond between N8 and the 2'-hydroxyl group of guanosine ribose. This hypothesis has been tested by a molecular mechanics calculation using a model structure of the complex between N8-actinomycin D and a small RNA:DNA hybrid, r(GC):d(GC). The results of the molecular mechanics calculation suggest that N8-actinomycin D can intercalatively bind to the RNA:DNA hybrid by making an additional intracomplex hydrogen bond. This hydrogen bonding capability of N8 has been confirmed in the crystal structure of the chromophore of N8-actinomycin D. Thus, N8-actinomycin D has been synthesized by coupling the pyridine and benzene fragments obtained independently. A binding study indicates that both actinomycin D and N8-actinomycin D bind intercalatively not only to DNA:DNA double strands but also to RNA:DNA hybrids. Although the overall binding capacity of N8-actinomycin D is reduced substantially in comparison with that of actinomycin D itself, N8-actinomycin D tends to bind relatively more favorably than actinomycin D to the RNA:DNA hybrids. Thus, this initial attempt at designing an RNA:DNA hybrid binding agent appears to be successful. However, it is necessary to modify the agent further to increase its RNA:DNA hybrid binding character and to decrease the DNA:DNA binding character, in order to make a useful RNA:DNA hybrid binding agent.

Studies on 2-aziridinecarboxylic acid. VIII. Total synthesis of actinomycin D and its serine analogue via ring-opening reaction of 1-benzyloxycarbonyl-2-aziridinecarboxylic acid moiety

-